Filgrastim biosimilar - Ratiopharm/Teva

Drug Profile

Filgrastim biosimilar - Ratiopharm/Teva

Alternative Names: Biograstim (Teva); Filgrastim BS Inj.; Filgrastim NK; Granix; Leucocyte growth factor - Teva; Leukocyte growth factor - Teva; Neutroval™; Ratiograstim; Short-acting G-CSF - Teva; Short-acting Granulocyte Colony Stimulating Factor - Teva; tbo-filgrastim; Tevagrastim; XM-02; XM02-filgrastim

Latest Information Update: 08 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ratiopharm; SICOR Biotech UAB
  • Developer Nippon Kayaku; Ratiopharm; SICOR Biotech UAB; Teva Pharmaceutical Industries; Teva Pharmaceuticals Europe; Teva-KOWA-Pharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 06 Aug 2018 Registered for Neutropenia (In adolescents, In children, In infants) in USA (SC)
  • 06 Aug 2018 Teva Pharmaceutical Industries plans to launch Granix® vials for Neutropenia (In adolescents, In children, In infants) in USA
  • 09 Dec 2017 Adverse events and immunogenecity data from a phase II trial in Neutropenia (In pediatrics) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top